Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome

Vitaly Smelov, T. Perekalina, N. Artemenko, N. Smelova, G. Ukleeva, A. Gorelov

Результат исследований: Научные публикации в периодических изданияхстатья

2 Цитирования (Scopus)

Выдержка

Fluoroquinolones are recommended in the therapy of chronic prostatitis. Chlamydia trachomatis is one of the possible aetiological agents of chronic prostatitis. However, little is known about chlamydia survival in the presence of fluoroquinolones in patients with chronic prostatitis syndrome. For the first time, chlamydia survival in vitro in the presence of lomefloxacin (LOMX) (mostly recommended in the treatment of chronic prostatitis) versus levofioxacin (LVFX) (recommended in the therapy against chlamydia infection) is examined and analysed in the 33 chlamydia-infected patients with chronic prostatitis syndrome in this study. Antichlamydial activity in vitro of LOMX in patients with C. trachomatis and prostatitis was found to be more effective than LVFX. However, further clinical trials for these agents are recommended.

Язык оригиналаанглийский
Страницы (с-по)61-64
Число страниц4
ЖурналAndrologia
Том37
Номер выпуска2
DOI
СостояниеОпубликовано - 1 дек 2005

Отпечаток

Prostatitis
Levofloxacin
Chlamydia trachomatis
Fluoroquinolones
Survival
Chlamydia
Chlamydia Infections
lomefloxacin
Therapeutics
Clinical Trials

Предметные области Scopus

  • Эндокринология
  • Урология

Цитировать

@article{34dd6c35a80e41e6a2cda73759e0301e,
title = "Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome",
abstract = "Fluoroquinolones are recommended in the therapy of chronic prostatitis. Chlamydia trachomatis is one of the possible aetiological agents of chronic prostatitis. However, little is known about chlamydia survival in the presence of fluoroquinolones in patients with chronic prostatitis syndrome. For the first time, chlamydia survival in vitro in the presence of lomefloxacin (LOMX) (mostly recommended in the treatment of chronic prostatitis) versus levofioxacin (LVFX) (recommended in the therapy against chlamydia infection) is examined and analysed in the 33 chlamydia-infected patients with chronic prostatitis syndrome in this study. Antichlamydial activity in vitro of LOMX in patients with C. trachomatis and prostatitis was found to be more effective than LVFX. However, further clinical trials for these agents are recommended.",
keywords = "Chlamydia trachomatis, Levofloxacin, Lomefloxacin, Prostatitis",
author = "Vitaly Smelov and T. Perekalina and N. Artemenko and N. Smelova and G. Ukleeva and A. Gorelov",
year = "2005",
month = "12",
day = "1",
doi = "10.1111/j.1439-0272.2005.00654.x",
language = "English",
volume = "37",
pages = "61--64",
journal = "Andrologia",
issn = "0303-4569",
publisher = "Wiley-Blackwell",
number = "2",

}

Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome. / Smelov, Vitaly; Perekalina, T.; Artemenko, N.; Smelova, N.; Ukleeva, G.; Gorelov, A.

В: Andrologia, Том 37, № 2, 01.12.2005, стр. 61-64.

Результат исследований: Научные публикации в периодических изданияхстатья

TY - JOUR

T1 - Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome

AU - Smelov, Vitaly

AU - Perekalina, T.

AU - Artemenko, N.

AU - Smelova, N.

AU - Ukleeva, G.

AU - Gorelov, A.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Fluoroquinolones are recommended in the therapy of chronic prostatitis. Chlamydia trachomatis is one of the possible aetiological agents of chronic prostatitis. However, little is known about chlamydia survival in the presence of fluoroquinolones in patients with chronic prostatitis syndrome. For the first time, chlamydia survival in vitro in the presence of lomefloxacin (LOMX) (mostly recommended in the treatment of chronic prostatitis) versus levofioxacin (LVFX) (recommended in the therapy against chlamydia infection) is examined and analysed in the 33 chlamydia-infected patients with chronic prostatitis syndrome in this study. Antichlamydial activity in vitro of LOMX in patients with C. trachomatis and prostatitis was found to be more effective than LVFX. However, further clinical trials for these agents are recommended.

AB - Fluoroquinolones are recommended in the therapy of chronic prostatitis. Chlamydia trachomatis is one of the possible aetiological agents of chronic prostatitis. However, little is known about chlamydia survival in the presence of fluoroquinolones in patients with chronic prostatitis syndrome. For the first time, chlamydia survival in vitro in the presence of lomefloxacin (LOMX) (mostly recommended in the treatment of chronic prostatitis) versus levofioxacin (LVFX) (recommended in the therapy against chlamydia infection) is examined and analysed in the 33 chlamydia-infected patients with chronic prostatitis syndrome in this study. Antichlamydial activity in vitro of LOMX in patients with C. trachomatis and prostatitis was found to be more effective than LVFX. However, further clinical trials for these agents are recommended.

KW - Chlamydia trachomatis

KW - Levofloxacin

KW - Lomefloxacin

KW - Prostatitis

UR - http://www.scopus.com/inward/record.url?scp=25444496792&partnerID=8YFLogxK

U2 - 10.1111/j.1439-0272.2005.00654.x

DO - 10.1111/j.1439-0272.2005.00654.x

M3 - Article

C2 - 16026425

AN - SCOPUS:25444496792

VL - 37

SP - 61

EP - 64

JO - Andrologia

JF - Andrologia

SN - 0303-4569

IS - 2

ER -